louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01100788: Satiety Response of Short Chain Fructooligosaccharide
Official title: Satiety Response of Short Chain Fructooligosaccharide
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Healthy
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2010-04-09
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Populations that report high fiber consumption demonstrate lower rates of obesity. Enhanced satiety may play a key role in this relationship. The colonic fermentation of fibers is theorized to influence satiety and food intake. Short chain fructooligosaccharide (scFOS) are rapidly fermentable fibers that can easily be added to foods to impact these parameters.

The objective of this study was to evaluate the satiety response of scFOS and its ability to decrease food intake.

Detailed description: Intervention study with fiber added to beverages and acute effects on satiety measured.

Eligibility criteria: Inclusion Criteria:

* Healthy men and women
* Age 18-64 years
* Non-smoking
* Not taking medication
* Non-dieting (weight stable in prior 3 months)
* BMI 18-27
* English literacy

Exclusion Criteria:

* Do not regularly consume breakfast
* Food allergies to ingredients found in study products
* BMI \<18 or \>27
* Diagnosed cardiovascular, renal, or hepatic disease diabetes mellitus
* Cancer in previous 5 years (except basal cell carcinoma of the skin)
* Any gastrointestinal disease or condition
* Recent bacterial infection (\< 3 months)
* Recent or concurrent participation in an intervention research study
* History of drug or alcohol abuse in prior 6 months
* Use of lipid-lowering, anti-hypertensive, or anti-inflammatory steroid medication
* Eating disorder
* Vegetarians
* People who eat more than approximately 15 grams of fiber per day
* Women who are pregnant or lactating
* Women with irregular menstrual cycles

Primary outcomes:
measure: Satiety response using visual analogue scales
timeFrame: 0, 15, 30, 45, 60, 90, 120, 180, 240 minutes postprandially
Secondary outcomes:
measure: Ad libitum food intake
timeFrame: 240 minutes postprandially and over 24 hours
measure: Breath hydrogen response
timeFrame: 0, 240 minutes
measure: Gastrointestinal tolerance using visual analogue scales (VAS)
timeFrame: 24 hours
Other outcomes:
Locations:
city: Saint Paul
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Joanne Slavin
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06077188: EFFECT of CHEWING GUM on CONTROLLING NAUSEA/VOMITING and THIRST in PATIENTS with ACUTE PANCREATITIS
Official title: Erciyes University
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Pancreatitis
Thirst
Keywords: Acute Pancreatitis
Thirst
nouse
vomiting
Lead sponsor: TC Erciyes University
Sponsor class: OTHER
First posted: 2023-10-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Nausea and vomiting are one of the most common symptoms in acute pancreatitis. In addition to pharmacological methods for nausea and vomiting, non-pharmacological methods can also be used. Among these, anticipatory nausea and vomiting can be prevented by behaviors aimed at distracting attention. This study will be conducted to evaluate the effect of chewing gum on the severity of nausea-vomiting and thirst in patients with acute pancreatitis. The study will be conducted with a total of 60 patients, 30 intervention and 30 control.

Patients in the intervention group will chew xylitol gum five times a day for three days. The patients' thirst and nausea and vomiting conditions will be examined.


Eligibility criteria: Inclusion Criteria:

* Those diagnosed with acute pancreatitis,

  * Without total dental prosthesis,
  * Without salivary gland infection,
  * Those who have not had salivary gland surgery,
  * No difficulty in chewing,
  * Not receiving oxygen therapy,
  * Able to answer all questions and be communicativ

Exclusion Criteria:

* Those with diabetes,
* Does not like chewing gum,
* Receiving radiotherapy or chemotherapy,

Primary outcomes:
measure: Thirst Severity -Visual Analog Scale
timeFrame: Apply in the morning of the 1st day after application
Secondary outcomes:
measure: Rhodes Nausea, Vomiting and Retching Index
timeFrame: Apply in the morning of the 1st day after application
measure: Rhodes Nausea, Vomiting and Retching Index (
timeFrame: Apply in the morning of the 1st day after application
Other outcomes:
Locations:
city: Kayseri
country: Turkey
facility: Erciyes University Hospital
Study officials:
References:
citation: Jensdottir T, Buchwald C, Nauntofte B, Hansen HS, Bardow A. Saliva in relation to dental erosion before and after radiotherapy. Acta Odontol Scand. 2013 May-Jul;71(3-4):1008-13. doi: 10.3109/00016357.2012.741704. Epub 2012 Nov 21.
citation: Oyetola EO, Owotade FJ, Agbelusi GA, Fatusi OA, Sanusi AA. Oral findings in chronic kidney disease: implications for management in developing countries. BMC Oral Health. 2015 Feb 20;15:24. doi: 10.1186/s12903-015-0004-z.
citation: Silva AC, Aprile LR, Dantas RO. EFFECT OF GUM CHEWING ON AIR SWALLOWING, SALIVA SWALLOWING AND BELCHING. Arq Gastroenterol. 2015 Jul-Sep;52(3):190-4. doi: 10.1590/S0004-28032015000300007.
citation: Honarmand M, Farhad-Mollashahi L, Nakhaee A, Sargolzaie F. Oral manifestation and salivary changes in renal patients undergoing hemodialysis. J Clin Exp Dent. 2017 Feb 1;9(2):e207-e210. doi: 10.4317/jced.53215. eCollection 2017 Feb.
Clinical trial NCT01064388: A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days
Official title: A Phase I, Single Center, Double-blind Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous AZD9742 After Administration of Multiple Ascending Doses for 14 Days in Healthy Male and Female Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Safety
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-02-08
Enrollment: 36
Sex: ALL
Minimum age (years): 23
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety, tolerability and blood levels of AZD9742 after daily dosing for 14 days.


Eligibility criteria: Inclusion Criteria:

* BMI between 19-30

Exclusion Criteria:

* Positive Fecal Occult Blood Test
* Prescriptions that inhibit liver function
* Received flu/H1N1 vaccine within 2 weeks before first dose

Primary outcomes:
measure: Safety variables (adverse events, vital signs, physical examinations, clinical laboratory assessments, 12-lead ECG, digital ECG, telemetry)
timeFrame: collected prior to treatment, during treatment and follow-up for a total of 25-30 days.
Secondary outcomes:
measure: To characterize the Pharmacokinetics of AZD9742 in blood and urine
timeFrame: PK-sampling during 14 pre-defined study days for PK profiling
Other outcomes:
Locations:
city: Overland Park
country: United States
facility: Research Site
state: Kansas
Study officials:
affiliation: AstraZeneca
name: Andrew Shaw
role: STUDY_DIRECTOR
affiliation: AstraZeneca
name: Brendan Smyth
role: STUDY_CHAIR
affiliation: AstraZeneca
name: David Melnick
role: STUDY_DIRECTOR
affiliation: Quintiles, Inc.
name: Ralph Schutz
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02845388: Sildenafil Citrate in Frozen Embryo Transfer
Official title: Sildenafil Citrate for Endometrial Preparation in Frozen-thawed Embryo Transfer Cycles
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Infertility
Keywords: IVF
Lead sponsor: Ain Shams Maternity Hospital
Sponsor class: OTHER
First posted: 2016-07-27
Enrollment: 90
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 37
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Comparison between usage of Sildenafil citrate with estradiol valerate or estradiol valerate alone in endometrial preparation and outcome of frozen-thawed embryo transfer cycles.


Eligibility criteria: Inclusion Criteria:

* all cases have at least 2 good quality blastocysts available for transfer

Exclusion Criteria:

* uterine structural abnormalities
* advanced uterine disease
* hydrosalpinx and pyosalpinx

Primary outcomes:
measure: endometrial pattern
timeFrame: starting from 8th day till 12th day of the menstrual cycle
Secondary outcomes:
measure: endometrial thickness
timeFrame: starting from 8th day till 12th day of menstrual cycle
measure: biochemical pregnancy test
timeFrame: 2 weeks after embryo transfer
Other outcomes:
Locations:
Study officials:
affiliation: department of obstetric and gynacology Ain shams university
name: Alaa mohamed elghannam, professor
role: STUDY_CHAIR
References:
Clinical trial NCT00301288: A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL).
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non-Hodgkins Lymphoma
Lead sponsor: Royal Marsden NHS Foundation Trust
Sponsor class: OTHER
First posted: 2006-03-10
Enrollment: 152
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 152 participants with Non-Hodgkin's Lymphoma who have received an autologous stem cell trandplant in the past and have written informed consent.

Brief summary: Patients with aggressive Non-Hodgkin-lymphoma treated at first diagnosis with chemotherapy alone or combined chemo-radiotherapy can achieve high response rates. However, patients with relapsed lymphoma still have a poor prognosis. High dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is the treatment of choice for these patients. An ASCT allows patients to receive much higher doses of chemotherapy than usual, to improve the chances of curing the disease. The high-dose of chemotherapy destroys the cells in the patients bone marrow and then the patients own cells from either the bone marrow or peripheral blood are used to rescue the patient from intensive treatment. High-dose chemotherapy with autologous stem cell (either bone marrow or peripheral blood) transplantation is used in the treatment of Intermediate/High grade NHL with poor risk disease and in second remission at the Royal Marsden Hospital.

The purpose of the present analysis is to determine independent prognostic factors correlated with the long-term outcome of patients with NHL who received an ASCT between January 1991 and June 2005. Accrual of eligible patients currently under follow-up will be performed in clinic at the time of next appointment. All patients accrued will give informed consent to participate in the study for retrospective case note review, after discussion with a study investigator and after receiving a study information sheet. The results of the analysis will be published in a peer-reviewed medical journal. This will include patients treated at the royal Marsden Hospital only.


Eligibility criteria: Inclusion Criteria:

- a) Age over 18 b) Patients with Non-Hodgkin's Lymphoma who have received an autologous stem cell transplant in the past.

c) Informed written consent

Exclusion Criteria:

* a) Medical or psychiatric conditions that compromise the patient's ability to give informed consent b) HIV positive or AIDS related lymphoma

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Sutton
country: United Kingdom
facility: Royal Marsden NHS trust
state: Surrey
Study officials:
affiliation: Royal Marsden NHS Foundation Trust
name: David Cunningham, FRCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06942988: Efficacy of Intracavernous Platelet-rich Plasma Injection in the Treatment of Erectile Dysfunction
Official title: Efficacy of Intracavernous Platelet-rich Plasma Injection in the Treatment of Erectile Dysfunction
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Erectile Dysfunction
Keywords: platelet-rich plasma
Erectile Dysfunction
Lead sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Sponsor class: OTHER_GOV
Collaborators: name: t-biyoteknoloji labaratuvar estetik medikal kozmetik san. ve tic. ltd. şti.
First posted: 2025-04-24
Enrollment: 34
Sex: MALE
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Investigation of the efficacy of autologous platelet-rich plasma administration on the potency of patients with vasculogenic and/or neurogenic erectile dysfunction


Eligibility criteria: Inclusion Criteria:

- 1)40-70 years old male, sexually active heterosexual, 2) Patients with a diagnosis of mild to moderate erectile dysfunction (IIEF score between 8-21) according to the International Index of Erectile Function (IIEF) for at least 3 months, 3) Patients who cannot achieve an erection despite peroral PDE5 inhibitor and intracavernous alprostadil injection therapy

Exclusion Criteria:

1. Patients with psychogenic erectile dysfunction, 2) Patients with a history of priapism, penile fracture, peyronie, penile curvature 3) Patients with a history of radical prostatectomy, 4) Patients with a history of major pelvic trauma, surgery, radiotherapy, 5) Patients with a history of malignancy affecting survival, 6) Patients with severe psychiatric illness that impairs adherence to treatment, 7) Patients with any bleeding disorder or on anti-aggregants/coagulants.

Primary outcomes:
measure: IIEF
timeFrame: 6 months
Secondary outcomes:
measure: FSFI
timeFrame: 6 months
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: University of Health Sciences, Bakırköy Sadi Konuk Training and Research Hospital
Study officials:
References:
Clinical trial NCT03139188: Palliative Care Unit Transfert Announcements
Official title: Palliative Care Transfer Announcements: Qualitative Analysis of the Perspective of Physicians and Their Patients With Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cancer
Keywords: Cancer
incurable pathologies
palliative care
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2017-05-03
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients over 18 years old with solid cancer or malignant haemopathy in palliative phase transferred from a HUS service to the HUS UnASP

Brief summary: The course of care of a patient with a cancer whose evolution is pejorative, is marked by difficult announcements, called "bad news". In the palliative phase, prognostic announcements are at the forefront. Of these, the announcement of a transfer to the Palliative Care Unit has not been the subject of any specific studies to the best of our knowledge. It therefore seemed interesting to us to explore the stakes of this particular announcement, a source of upheaval for the doctor and the patient, by gathering the point of view of each one.

The objective of our study is to analyze the methods of announcing a transfer to the Palliative Care Unit and the perception of this announcement by the doctor and his patient with an incurable cancer.


Eligibility criteria: Inclusion Criteria:

* Patients over 18 years old with solid cancer or malignant haemopathy in palliative phase transferred from a HUS service to the HUS UnASP and informed of this transfer by the originating doctor .

HUS senior hospital doctors, supporting patients with solid cancers or malignant hemopathies.

Exclusion Criteria:

* Patients whose clinical state does not allow for maintenance (tiredness, confusion) or difficult communication.

Primary outcomes:
measure: Analysis of semi-structured interviews exploring how the physician analyzes and feels the announcement of the transfer to the Palliative Care Unit and how the patient receives and disseminates this information
timeFrame: 72 hours after the transfer of the patient the to the Palliative Care Unit
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service : Unité de soins d'Accompagnement de soins de Support et de soins Palliatifs (UnASP)
city: Strasbourg
country: France
facility: Service : Unité de soins d'Accompagnement de soins de Support et de soins Palliatifs (UnASP)
Study officials:
affiliation: University Hospital, Strasbourg, France
name: Virginie LEROY, MD
role: STUDY_DIRECTOR
affiliation: University Hospital, Strasbourg, France
name: Laurent CALVEL, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05191888: 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy
Official title: 14-day PCAB-based and Reverse Hybrid Therapy Fro Helicobacter Pylori
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Helicobacter Pylori Eradication
Lead sponsor: Kaohsiung Medical University
Sponsor class: OTHER
First posted: 2022-01-14
Enrollment: 906
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 1. 14-day vonoprazan high-dose two-in-one therapy
2. 14-day vonoprazan triple therapy
3. 14th Rabeprazole reverse mixed therapy
Primary purpose: TREATMENT

Brief summary: 1. Test for Helicobacter pylori. The test items include urease test, histology, bacterial culture, serology, and urea breath test. At least two positive results can be used to confirm the diagnosis.
2. To ensure that the research results are not artificially distorted, this trial is a randomized study. Random allocation (which means that the subjects will use the "random number table generated by a computer similar to the lottery" to determine the treatment group) accept one of the following schemes (1:1:1).

Detailed description: Helicobacter pylori (H.pylori) infect more than 50% of humans globally. This study were (1) to test whether the efficacies of 14-day PCAB-based high-dose dual therapy and 14-day PPI-based reverse hybrid therapy can achieve a higher eradication rate than 14-day PCAB-based triple therapy in the first-line treatment of H pylori infection, (2) to compare the eradication rates of 14-day PCAB-based and PPI-based bismuth quadruple therapies in the second-line treatment of H pylori infection, and (3) to examine the impacts of antibiotic resistance of H pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H pylori treatments.

Eligibility criteria: Inclusion Criteria:

Subjects infected with Helicobacter pylori.

Exclusion Criteria:

1. Those who have ever received Helicobacter pylori sterilization treatment.
2. Those who are allergic to the drugs used in this research.
3. Those who have had stomach surgery.
4. Those with severe liver cirrhosis or uremia or malignant tumors.
5. Women who are pregnant or breastfeeding.

Primary outcomes:
measure: the rate of Helicobacter pylori
timeFrame: 6 week after finishing study drugs
Secondary outcomes:
measure: Adverse drug reactions
timeFrame: 2weeks after finishing study drugs
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Hospital
Study officials:
References:
Clinical trial NCT01628588: Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glaucoma, Open-Angle
Ocular Hypertension
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2012-06-27
Enrollment: 854
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with primary open angle glaucoma or ocular hypertension

Brief summary: This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).


Eligibility criteria: Inclusion Criteria:

* Diagnosis of primary open angle glaucoma or ocular hypertension
* Prescribed Lumigan®

Exclusion Criteria:

* None

Primary outcomes:
measure: Change From Baseline in Intraocular Pressure (IOP)
timeFrame: Baseline, 14 Weeks
Secondary outcomes:
measure: Patient Assessment of Tolerability Using a 4-Point Scale
timeFrame: 14 Weeks
measure: Physician Assessment of Tolerability Using a 4-Point Scale
timeFrame: 14 Weeks
measure: Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks
timeFrame: 14 Weeks
measure: Patients Who Will Continue Use of Lumigan® After 14 Weeks
timeFrame: 14 Weeks
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT04433988: Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients
Official title: Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: COVID
Lead sponsor: Sadat City University
Sponsor class: OTHER
First posted: 2020-06-16
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: With potential antiviral effects on severe acute respiratory syndrome (SARS) and as a methyl-xanthine derived inhibitor of phosphodiesterase-4, pentoxifylline basically functions as a hemorrheologic agent for a better circulation and oxygenation and exerts unique effects on immune modulation, inflammation and oxidative stress. As the main regulator of cAMP metabolism, posphodiesterase-4 plays a key role in proinflammatory and immune cells. Pentoxifylline plays its anti-inflammatory role by reducing the production of proinflammatory cytokines such as TNF-a, IL-1 and IL-6. Given its unique impacts on immune modulation, homeostasis and fibrinolysis and its supportive effects on oxidative stress and organ failure, pentoxifylline can constitute a multipurpose and generally-safe adjuvant therapy for COVID-19 patients.


Eligibility criteria: Inclusion Criteria:

* Positive COVID-19 test
* Age \>/= 18 y.o.

Exclusion Criteria:

* Allergic reaction to Pentoxifylline
* Ongoing anticoagulation
* History of GI bleeding
* History of Seizures
* Cardiac or other vascular stents
* History of severe renal disease
* History of intracranial hemorrhage.

Primary outcomes:
measure: Primary Outcome
timeFrame: 7 days
Secondary outcomes:
measure: Respiratory infection
timeFrame: 7 days
measure: Serious Adverse Events
timeFrame: 7 days
Other outcomes:
Locations:
city: Shibīn Al Kawm
country: Egypt
facility: Faculty of Medicine
Study officials:
References: